Media headlines about OncoMed Pharmaceuticals (NASDAQ:OMED) have trended positive on Friday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoMed Pharmaceuticals earned a news impact score of 0.26 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.1724305305396 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- $6.51 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter (americanbankingnews.com)
- -$0.24 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter (americanbankingnews.com)
- Oncomed Pharmaceuticals (OMED) Lifted to Buy at Zacks Investment Research (americanbankingnews.com)
- Oncomed Pharmaceuticals (OMED) Downgraded to Hold at Zacks Investment Research (americanbankingnews.com)
Shares of OMED opened at $3.16 on Friday. OncoMed Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $8.99. The firm has a market cap of $117.07, a PE ratio of -3.04 and a beta of 1.82.
Several research firms recently commented on OMED. Cantor Fitzgerald set a $6.00 target price on shares of OncoMed Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, January 4th. Zacks Investment Research raised shares of OncoMed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Thursday, January 4th. Finally, HC Wainwright restated a “hold” rating and issued a $3.00 price target on shares of OncoMed Pharmaceuticals in a research report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $5.31.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/04/06/oncomed-pharmaceuticals-omed-receives-daily-coverage-optimism-score-of-0-26/2030269.html.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer.
Receive News & Ratings for OncoMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.